ROCKET AF Yields Positive Results For Xarelto, But A Few Chinks In The Armor

Bayer/J&J’s factor Xa inhibitor Xarelto (rivaroxaban) met its endpoints in the head-to-head ROCKET AF study against warfarin, but on some major bleeding outcomes measures it actually did worse than warfarin, and the effects of the widely used generic appear to have been sub-par in the 14,000-patient study.